Back

Outcomes of empagliflozin versus dapagliflozin treatment in patients with heart failure based on left ventricular ejection fraction: a multicentre cohort study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (4) - Pharmacotherapy for heart failure (2) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Hyo-Suk Ahn

Uijeongbu St. Mary's Hospital, Seoul (Korea (Republic of))

6 More presentations in this session

Presentation thumbnail
Discussant - Pharmacotherapy for heart failure (2)
Presentation thumbnail
Optimizing pharmacotherapy in heart failure: a pharmacist-mediated, multidisciplinary team approach in an advanced heart failure centre
Ms E. Lozo (Zagreb, HR)
Abstract Slides Video
Presentation thumbnail
Response of patients after biventricular upgrade from right ventricular pacing
Doctor E. Merkel (Budapest, HU)
Abstract
Presentation thumbnail
Real-world treatment patterns and uptitration in De Novo heart failure with reduced ejection fraction. insights from the comfe registry
Mr A. Caamano Noya (Santiago de Compostela, ES)
Abstract Slides Video
Presentation thumbnail
Early experience with finerenone in patients with heart failure and diabetic kidney disease: 6 months of real-world cohort follow-up
Mr E. Boada Lincango (A Coruna, ES)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (4) - Pharmacotherapy for heart failure (2)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Session
Pharmacotherapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources